Clinical Data Intellia finds genetic suspect for liver safety signals with ATTR gene therapy BioSpaceIn November 2025, one patient died after receiving Intellia Therapeutics' investigational gene silencer for transthyretin amyloidosis.Rare DiseaseRead full story pharminent August 7, 2026 (Last updated: August 8, 2026) BioSpace In November 2025, one patient died after receiving Intellia Therapeutics’ investigational gene silencer for transthyretin amyloidosis. Rare Disease Read full story Post navigation Previous: Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatmentsNext: Replimune Readies Launch of Newly Approved Melanoma Therapy Tudriqev Related Stories Clinical Data Spyre deprioritises arthritis drug after Phase 2 results pharminent August 26, 2026 Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026
